[HTML][HTML] Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile …
LA Leiter, SC Bain, I Hramiak, E Jódar… - Cardiovascular …, 2019 - Springer
Background The SUSTAIN 6 trial demonstrated that once-weekly semaglutide (0.5 and 1.0
mg) significantly reduced major adverse cardiovascular (CV) events (MACE) vs placebo in …
mg) significantly reduced major adverse cardiovascular (CV) events (MACE) vs placebo in …
Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the …
LA Leiter, SC Bain, I Hramiak, E Jódar… - Cardiovascular …, 2019 - search.proquest.com
Table 1 Baseline characteristics and demographics of subjects in the SUSTAIN 6 trial A.
Post hoc analysis by gender Semaglutide Placebo Male Female Male Female Subject …
Post hoc analysis by gender Semaglutide Placebo Male Female Male Female Subject …
[HTML][HTML] Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile …
LA Leiter, SC Bain, I Hramiak, E Jódar… - Cardiovascular …, 2019 - ncbi.nlm.nih.gov
Background The SUSTAIN 6 trial demonstrated that once-weekly semaglutide (0.5 and 1.0
mg) significantly reduced major adverse cardiovascular (CV) events (MACE) vs placebo in …
mg) significantly reduced major adverse cardiovascular (CV) events (MACE) vs placebo in …
Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the …
LA Leiter, SC Bain, I Hramiak, E Jódar… - Cardiovascular …, 2019 - europepmc.org
Background The SUSTAIN 6 trial demonstrated that once-weekly semaglutide (0.5 and 1.0
mg) significantly reduced major adverse cardiovascular (CV) events (MACE) vs placebo in …
mg) significantly reduced major adverse cardiovascular (CV) events (MACE) vs placebo in …
Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: A post hoc analysis of gender, age, and baseline CV risk profile in the …
LA Leiter, SC Bain, I Hramiak, E Jódar, S Madsbad… - comm.ku.dk
Background: The SUSTAIN 6 trial demonstrated that once-weekly semaglutide (0.5 and 1.0
mg) significantly reduced major adverse cardiovascular (CV) events (MACE) vs placebo in …
mg) significantly reduced major adverse cardiovascular (CV) events (MACE) vs placebo in …
Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the …
LA Leiter, SC Bain, I Hramiak, E Jódar… - Cardiovascular …, 2019 - search.ebscohost.com
Background: The SUSTAIN 6 trial demonstrated that once-weekly semaglutide (0.5 and 1.0
mg) significantly reduced major adverse cardiovascular (CV) events (MACE) vs placebo in …
mg) significantly reduced major adverse cardiovascular (CV) events (MACE) vs placebo in …
Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the …
LA Leiter, SC Bain, I Hramiak, E Jodar… - Cardiovascular …, 2019 - go.gale.com
Background The SUSTAIN 6 trial demonstrated that once-weekly semaglutide (0.5 and 1.0
mg) significantly reduced major adverse cardiovascular (CV) events (MACE) vs placebo in …
mg) significantly reduced major adverse cardiovascular (CV) events (MACE) vs placebo in …
Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: A post hoc analysis of gender, age, and baseline CV risk profile in the …
LA Leiter, SC Bain, I Hramiak… - Cardiovascular …, 2019 - utsouthwestern.elsevierpure.com
Background: The SUSTAIN 6 trial demonstrated that once-weekly semaglutide (0.5 and 1.0
mg) significantly reduced major adverse cardiovascular (CV) events (MACE) vs placebo in …
mg) significantly reduced major adverse cardiovascular (CV) events (MACE) vs placebo in …
[PDF][PDF] Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in …
LA Leiter, SC Bain, I Hramiak, E Jódar, S Madsbad… - 2019 - academia.edu
Background: The SUSTAIN 6 trial demonstrated that once-weekly semaglutide (0.5 and 1.0
mg) significantly reduced major adverse cardiovascular (CV) events (MACE) vs placebo in …
mg) significantly reduced major adverse cardiovascular (CV) events (MACE) vs placebo in …
[PDF][PDF] Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in …
LA Leiter, SC Bain, I Hramiak, E Jódar, S Madsbad… - 2019 - core.ac.uk
Background: The SUSTAIN 6 trial demonstrated that once-weekly semaglutide (0.5 and 1.0
mg) significantly reduced major adverse cardiovascular (CV) events (MACE) vs placebo in …
mg) significantly reduced major adverse cardiovascular (CV) events (MACE) vs placebo in …